Vera Therapeutics, INC

Vera Therapeutics has appointed Nancy Bowman as Chief Regulatory Officer, succeeding William Turner who will transition to a Special Advisor role.

Vera Therapeutics announced FDA accelerated approval for TRUTAKNA to treat primary IgA nephropathy.

Vera Therapeutics announced an updated plan with the FDA for atacicept's IgA Nephropathy approval, expecting eGFR results in Q3 2026 and a supplemental BLA submission in Q4 2026.

Vera Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Vera Therapeutics announced Q1 2026 financial results, highlighting the FDA's Priority Review for atacicept in IgAN with a July 7, 2026 PDUFA date, and providing updates on corporate progress and upcoming milestones.

Vera Therapeutics announced positive Phase 3 data for atacicept in IgA nephropathy, received FDA priority review, and reported full year 2025 financial results including a net loss of $299.6 million.

Vera Therapeutics reported a net loss of $121.0 million for Q1 2026, with significant increases in R&D and G&A expenses, while advancing its lead product candidate, atacicept, for IgAN.

Vera Therapeutics reported significantly increased net losses and cash burn in Q3 2025, while advancing its lead product candidate, atacicept, with positive Phase 3 primary endpoint results and Breakthrough Therapy Designation.

Vera Therapeutics reports increased net losses in Q2 2025 as it advances its lead drug candidate, atacicept, through pivotal Phase 3 trials towards a planned Q4 2025 regulatory submission.

Vera Therapeutics reports a net loss of $51.7 million for Q1 2025, with significant R&D investment in its lead drug candidate, atacicept, and expects primary endpoint results in Q2 2025.

Vera Therapeutics' Q3 2024 filing reveals a significant increase in research and development expenses, primarily driven by manufacturing and clinical trial activities, alongside a substantial rise in cash and marketable securities.

Vera Therapeutics' Q2 2024 filing reveals increased research and development expenses, primarily driven by clinical trial and manufacturing activities, alongside a follow-on public offering that significantly boosted cash reserves.

Vera Therapeutics submitted a Biologics License Application for its lead candidate, atacicept, for IgAN after positive Phase 3 results, receiving FDA Priority Review.

Vera Therapeutics advances atacicept for IgAN, anticipates Phase 3 results in Q2 2025, and expands its pipeline with VT-109 acquisition.

Vera Therapeutics details its common stock structure, voting rights, and anti-takeover provisions in a recent SEC filing.

Vera Therapeutics President and CEO, Marshall Fordyce, reported the sale of over 46,000 shares of Class A Common Stock through a pre-arranged 10b5-1 trading plan.

Vera Therapeutics President and CEO Marshall Fordyce sold a significant number of Class A Common Stock shares under a pre-arranged trading plan.

Vera Therapeutics Director Scott W. Morrison was granted stock options for 17,084 shares of Class A Common Stock.

Andrew Cheng, a Director at Vera Therapeutics, Inc., acquired 17,084 stock options with an exercise price of $34.35, vesting in full on May 20, 2036, or earlier upon a change in control.

Beth C. Seidenberg, a Director at Vera Therapeutics, Inc., acquired stock options for 17,084 shares of Class A Common Stock.

Vera Therapeutics Director Christy J. Oliger acquired 17,084 stock options with an exercise price of $34.35, vesting under specific conditions related to service and company events.

Vera Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders, to be held virtually on May 21, 2026, with key proposals including director elections and auditor ratification.

Vera Therapeutics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Vera Therapeutics sets its 2025 Annual Meeting for May 14, outlining proposals for director elections, auditor ratification, executive compensation, and vote frequency.

Vera Therapeutics has amended its non-employee director compensation policy to reduce the size of equity awards granted to non-employee directors.

Vera Therapeutics, Inc. has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Vera Therapeutics announces its 2024 Annual Meeting of Stockholders to be held on May 15, 2024, featuring the election of directors and ratification of the company's independent accounting firm.

Sofinnova Venture Partners X and affiliated entities have reduced their beneficial ownership in Vera Therapeutics, Inc. to below 5% due to dilution and open market sales.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has disclosed a 1.7% beneficial ownership stake in Vera Therapeutics, Inc.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Vera Therapeutics Inc. following an internal realignment.

T. Rowe Price Associates, Inc. has disclosed an increased beneficial ownership of 7.7% in Vera Therapeutics Inc. common stock.

FMR LLC and Abigail P. Johnson have disclosed a 4.1% beneficial ownership stake in Vera Therapeutics Inc.'s Class A Common Stock as of December 31, 2025.

The Vanguard Group reported a 5.03% beneficial ownership stake in Vera Therapeutics Inc., holding 3,570,401 common shares as of December 31, 2025.

T. Rowe Price Associates, Inc. has increased its beneficial ownership in Vera Therapeutics Inc. to 5.7% of common stock as of September 30, 2025.